Cellectar Biosciences CLRB 深 滬
已收盤 02-06 16:00:00 美东时间
3.04
+0.220
+7.80%
華盛通- 最 高3.13
- 今 開2.85
- 成交量 4.61万股
- 最 低 2.85
- 昨 收 2.82
- 總市值 1289.00万
- 52周最高 20.595
- 市盈率 靜 --
- 換手率 1.09%
- 52周最低 2.45
- 委 比 65.88%
- 總股本 424.01万
- 歷史最高 276000.00
- 量 比 1.35
- 振 幅 9.93%
- 歷史最低 2.81
- 每 手 1
- 風險率 2.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
Cellectar Biosciences To Seek EMA Conditional Approval For Iopofosine I 131 In 3Q26; To Present Final CLOVER WaM Results, Advance CLR 125 Breast Cancer Study In 2026
Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Submit for Conditional
01-09 21:10
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Cellectar Biosciences announces plans to submit a Conditional Marketing Authorization (CMA) application for iopofosine I 131 in Europe by 3Q 2026, following EMA guidance, and advance U.S. regulatory strategy. The company highlights 2025 achievements, including FDA Breakthrough Therapy and Orphan Drug Designations for iopofosine I 131 in Waldenstrom’s macroglobulinemia (WM), successful pediatric glioma trial data, and initiation of a Phase 1b stud...
01-09 13:05
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Cellectar Biosciences has signed a multi-year supply agreement with Ionetix Corporation to secure clinical and commercial-scale supplies of Ac-225 and At-211, critical alpha-emitting radioisotopes. This collaboration supports Cellectar's drug development programs, particularly the targeted alpha therapy candidate CLR-225 for treating solid tumors like pancreatic cancer. Ionetix is expanding its cyclotron production to meet the growing demand for ...
2025-12-16 13:05
Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.53) by 44.2 percent. This is a 88.25 percent increase over losses of $(12.00) per share
2025-11-13 20:03
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cellectar Biosciences announced financial results for Q3 2025 and updates on its pipeline, including plans to submit a Conditional Marketing Authorization application for iopofosine I 131 in Europe for refractory Waldenstrom's macroglobulinemia in 2026. The company also initiated a Phase 1b study for CLR 125 in triple-negative breast cancer (TNBC) and received rare pediatric drug designation for iopofosine I 131 in inoperable relapsed/refractory ...
2025-11-13 12:20
Earnings Outlook For Cellectar Biosciences
Cellectar Biosciences (NASDAQ:CLRB) is set to give its latest quarterly earning...
2025-11-13 01:03
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Cellectar Biosciences, Inc. will report its third-quarter 2025 financial results and provide a corporate update on November 13, 2025, at 8:30 a.m. ET. A conference call and webcast will be held, accessible via 1-800-717-1738 (Conference ID: 42734) or the provided webcast link. A replay will be available on the company’s Investor Relations website. Cellectar focuses on developing radiopharmaceuticals for cancer treatment using its Phospholipid Dru...
2025-11-06 13:05
CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company received Rare Pediatric Disease designation from the FDA for Iopofosine I-131 in relapsed or refractory pediatric high-grade glioma.
CLRB stock has given up its prior gain. Cellectar Biosciences shares were tradi...
2025-10-27 21:27
